Mizuho Maintains Buy on Biogen, Lowers Price Target to $335
Portfolio Pulse from jenniferd'souza@benzinga.com
Mizuho analyst Salim Syed has maintained a 'Buy' rating on Biogen (NASDAQ:BIIB) but lowered the price target from $340 to $335.

August 14, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biogen's price target has been lowered by Mizuho from $340 to $335, though the 'Buy' rating is maintained.
While the lowering of the price target might be seen as a negative signal, the maintenance of the 'Buy' rating indicates that Mizuho still sees potential in Biogen. This could lead to a neutral short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100